Monopar Therapeutics (MNPR) Assets (2016 - 2020)
Historic Assets for Monopar Therapeutics (MNPR) over the last 5 years, with Q3 2020 value amounting to $18.2 million.
- Monopar Therapeutics' Assets rose 25540.08% to $18.2 million in Q3 2020 from the same period last year, while for Sep 2020 it was $18.2 million, marking a year-over-year increase of 25540.08%. This contributed to the annual value of $13.4 million for FY2019, which is 8245.56% up from last year.
- According to the latest figures from Q3 2020, Monopar Therapeutics' Assets is $18.2 million, which was up 25540.08% from $12.8 million recorded in Q2 2020.
- In the past 5 years, Monopar Therapeutics' Assets registered a high of $18.2 million during Q3 2020, and its lowest value of $2.9 million during Q4 2016.
- Over the past 5 years, Monopar Therapeutics' median Assets value was $8.4 million (recorded in 2018), while the average stood at $9.2 million.
- In the last 5 years, Monopar Therapeutics' Assets crashed by 3523.37% in 2019 and then skyrocketed by 25540.08% in 2020.
- Monopar Therapeutics' Assets (Quarter) stood at $2.9 million in 2016, then soared by 242.98% to $9.9 million in 2017, then dropped by 26.31% to $7.3 million in 2018, then surged by 82.46% to $13.4 million in 2019, then skyrocketed by 35.98% to $18.2 million in 2020.
- Its Assets was $18.2 million in Q3 2020, compared to $12.8 million in Q2 2020 and $12.8 million in Q1 2020.